Could a Validated Biomarker Transform the Lupus Market?Decision ResourcesDecember 19, 2006 21 Pages - SKU: DECR1399798 |
|
Introduction The identification of valid biomarkers for systemic lupus erythematosus (SLE) will be an important aid to companies developing drugs for SLE and may speed drug development in this market. Although no biomarkers are yet accepted and routinely used for any aspect of SLE, several promising SLE biomarkers are under investigation. Get the Answers You Need to Shape Your Strategy Biomarkers have the potential to play a valuable role in drug development for SLE. What impact would biomarkers have on SLE clinical trials? How could biomarkers help reduce the cost of developing SLE treatments? Which types of companies will see the greatest impact from the use of biomarkers? Biomarkers have tremendous potential in guiding treatment for SLE. How could biomarkers help guide physicians in their prescribing decisions? What role would diagnostic biomarkers and disease-activity biomarkers play? Many types of biomarkers are being developed, including genetic markers, markers of disease activity, and diagnostic markers. Which type of markers are likely to have the greatest nearterm impact for drug development? Which markers are the most promising? A prognostic biomarker of disease activity could lower treatment costs in SLE. How would biomarkers help reduce direct SLE costs? Indirect SLE costs? Scope
|
Additional Information
Mentioned in This Spectrum Report—Biomarkers
- Anti-dsDNA
- BLyS
- CD19+ B cells
- CD27 high plasma cells
- CD40 ligand + lymphocytes
- Complement activation products
- Complement component C2 defi ciency
- Complement defi ciencies
- FcãRIIIa polymorphisms
- FcãRIIa polymorphisms
- IL-6
- IL-10
- IL-12 p40
- IL-13
- IL-16
- IL-18
- Immune complexes
- Interferon-alpha
- Mannose-binding lectin (MBL)
- polymorphisms
- Soluble CD27
- Soluble CD40 ligand
- Soluble IL-2 receptor (CD25)
- Soluble thrombomodulin
- Soluble TNF receptor
- Soluble VCAM-1
- Anti-dsDNA
- BLyS
- CD19+ B cells
- CD27 high plasma cells
- CD40 ligand + lymphocytes
- Complement activation products
- Complement component C2 defi ciency
- Complement defi ciencies
- FcãRIIIa polymorphisms
- FcãRIIa polymorphisms
- IL-6
- IL-10
- IL-12 p40
- IL-13
- IL-16
- IL-18
- Immune complexes
- Interferon-alpha
- Mannose-binding lectin (MBL)
- polymorphisms
- Soluble CD27
- Soluble CD40 ligand
- Soluble IL-2 receptor (CD25)
- Soluble thrombomodulin
- Soluble TNF receptor
- Soluble VCAM-1
Related Markets
- Biotechnology
- Biomarkers
- Diseases & Conditions
- Autoimmune
- Pharmaceuticals
- Drug Discovery
- Therapeutic Area
- Women's Health
Women's Health Reports
- Triple Analysis: Breast Cancer, Pancreatic Cancer and Protein Kinase Inhibitors
- Triple Analysis: Breast Cancer, Melanoma and Protein Kinase Inhibitors
- Triple Analysis: Breast Cancer, Lymphoma and Protein Kinase Inhibitors
- Triple Analysis: Breast Cancer, Lung Cancer and Protein Kinase Inhibitors
- Triple Analysis: Breast Cancer, Leukemia and Protein Kinase Inhibitors
